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Imaging Lymph Nodes with Nanoparticles
DOI: 10.1371/journal.pmed.0010067
Accurate staging of cancers is one of the most important 
parts of the work up of patients for both prediction of 
prognosis and determination of the most appropriate 
treatment. And an essential part of this work up is assessing 
whether or not there has been lymphatic spread. Current 
methods include surgical removal of nodes for examination 
and various types of 
imaging, ranging from 
ultrasound to newer 
technologies such as 
magnetic resonance 
imaging (MRI). All 
these methods have 
problems; some 
are very invasive, 
others are very time 
consuming, and 
none are completely 
reliable. 
However in one 
of the more exciting 
crossovers from 
chemistry into 
medicine, researchers 
have developed 
nanoparticles to improve the diagnostic accuracy of MRI. 
The nanoparticles contain a central superparamagnetic 
iron oxide core and are covered by dextran, imparting 
long circulation times and biocompatibility. When injected 
intravenously, the nanoparticles localize to lymphoid tissue, 
and are internalized into macrophages. There is then a 
decrease in signal intensity on T2- and T2*-weighted images, 
and when metastases are present there is a recognizably 
abnormal pattern on MRI scans. 
In a previous paper published in the New England Journal 
of Medicine, Ralph Weissleder and colleagues described 
using these nanoparticles to assess lymphoid spread in 
patients with prostate cancer. Now, in a paper published 
in this month’s PLoS Medicine, they have gone further by 
extending the analysis to patients with different types 
of cancer, and producing an algorithm that allows semi-
automation of the procedure.
The authors developed the algorithm in a training 
group of 36 patients and then validated it in a group of 34 
patients. The results are encouraging: the analysis showed 
a sensitivity of 98% (95% conﬁ  dence interval, 88%–99%) 
and a speciﬁ  city of 92% (95% conﬁ  dence interval, 87%–
96%). The advantages of automating this procedure are 
substantial, not least because it can remove the problem of 
different observers assessing data differently.
And what is more, once the data have been collected and 
assessed it is possible to reconstruct a virtual picture of the 
patient’s lymph nodes, thus potentially allowing accurate 
surgical removal of the nodes. 
Harisinghani MG, Weissleder R (2004) Sensitive, noninvasive 
detection of lymph node metastases. DOI: 10.1371/journal.
pmed.0010066
Sleep Duration 
Affects Appetite-Regulating Hormones
DOI: 10.1371/journal.pmed.0010068
Some of us, when awake in the middle of the night, feel an urge 
to visit the kitchen. This could explain results of previous studies 
that have shown a link between short sleep duration and high body 
mass index (BMI). But a study by Emmanuel Mignot and colleagues 
suggests that it’s not just the additional snacking opportunities that 
make short sleepers more likely to be overweight. 
Intrigued by the connection between sleep and BMI, and by 
recent studies showing that sleep deprivation in laboratory settings 
can cause a decrease in serum levels of leptin, a hormone known to 
control appetite, Emmanuel Mignot and colleagues set out to study 
the levels of various hormones known to regulate appetite and 
energy expenditure under  “real life” conditions. 
They took advantage of the Wisconsin Sleep Cohort Study, an 
ongoing longitudinal study of sleep habits and disorders in the 
general population. The study began in 1989, when researchers 
mailed state employees aged 30–60 years a survey on sleep habits, 
health, and demographics. Mail surveys were repeated at 5-year 
intervals, and some of the respondents were recruited to sleep a night 
in the laboratory and undergo various tests. A number of participants 
were also asked to keep a sleep diary for 6 days. The study has already 
shown connections between sleep apnea and hypertension, and 
between menopause and sleep-disordered breathing. 
For their study, Mignot and colleagues measured sleep duration 
(habitual and immediately prior to blood sampling), BMI, and pre-
breakfast blood hormone levels in 1,024 participants. Consistent with 
previous studies, they found that in individuals who sleep less than 8 
hours (74% of all participants), BMI was inversely proportional to sleep 
duration. In addition, short sleep was associated with low leptin and 
high ghrelin levels (ghrelin is a hormone thought to stimulate food 
intake). These hormonal 
differences are likely to 
increase appetite, which 
could be responsible 
for the increased BMI in 
short sleepers. 
These ﬁ  ndings could 
explain, at least in part, 
why societies in which 
excess calories are much 
easier to come by than 
a good night’s sleep are 
more prone to obesity. 
Mignot and colleagues 
plan to test this in 
intervention studies 
where they make 
people sleep more 
and measure the effects on body mass.  “Good sleep, healthy eating 
habits, and regular exercise each may have important roles in ﬁ  ghting 
obesity in modern society,” suggests Mignot. 
Taheri S, Lin L, Austin D, Young T, Mignot E (2004) Short sleep duration 
is associated with reduced leptin, elevated ghrelin, and increased body 
mass index. DOI: 10.1371/journal.pmed.0010062
DOI: 10.1371/journal.pmed.0010067.g001
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Adverse side effects, viral resistance, and the high cost of 
antiretroviral therapies remain obstacles in the way of turning 
HIV/AIDS into a manageable chronic disease. Structured 
treatment interruptions (STIs) in individuals who have good 
viral control on therapy have been proposed as a strategy for 
overcoming these obstacles. The initial hope that STIs would 
help patients achieve greater viral control has so far not been 
supported by data from clinical trials, but interrupting treatment 
has also been proposed as a strategy to reduce the cost of long-
term therapy and drug-associated toxicity. 
Luis Montaner and colleagues now report results from a 
randomized trial of 42 participants (75% on their second to 
fourth regimen, 66% on regimens containing non-nucleoside 
reverse-transcriptase inhibitors) who received either continuous 
therapy for 40 weeks or three successive treatment interruptions 
of two, four, and six weeks, followed by a ﬁ  nal open-ended 
interruption for both groups. 
The study was designed to be able to detect a difference of 
four weeks or greater between the two groups for the time to 
viral rebound during the open-ended interruption—the primary 
outcome. No difference between the two groups was seen 
(median time for the group on continuous treatment was four 
weeks, and for the STI group was ﬁ  ve weeks). 
Secondary outcomes included serious adverse events 
(disease progression, acute retroviral syndrome, therapy failure, 
or opportunistic infections at any point in the study), changes 
in CD4 count on therapy, immune reconstitution changes (CD4 
recall responses and CD4 naïve/memory T cell distribution), 
and detection of viral mutations There were no study-related 
serious adverse events in either group and no increase of 
therapy failure in the STI arm. CD4 counts ﬂ  uctuated between 
the start and end of each monitored treatment interruption, 
but levels recovered after resuppression of virus, with retention 
of recall responses throughout. Viral resistance was detected 
in both groups (in seven of 21 patients in the continuous 
treatment group and ten of 21 patients in the STI group), but 
it was more commonly detected (50% versus 18%) in the STI 
group during the open-ended ﬁ  nal interruption, even though 
all subjects suppressed virus upon reinitiating the same 
therapy.
Possible risks and beneﬁ  ts of STIs remain controversial, 
but data from this and other published trials do not support 
short-term clinical beneﬁ  ts of treatment interruptions. However, 
because they do not see increased therapy failure and ﬁ  nd 
preservation of immune function in the STI group, the authors 
conclude that, in light of the possibility of reducing costs and 
drug-related toxicity, additional trials of STIs are warranted. 
Particularly important in the debate over the safety of STIs 
is whether the detection of resistant mutants should be of 
concern. The authors point out that all participants were able to 
resuppress the mutant virus when they resumed their previous 
drug regimens but state that it remains undetermined to what 
extent resistant mutations are a signal for future therapy failure. 
Moreover, viral replication and rebound—which eventually 
occurred in all participants—is seen by some researchers as 
inherently detrimental, and these experts argue that treatment 
interruptions are unsafe and their use should be discontinued. 
What seems clear is that STIs have no place outside controlled 
clinical trials and that questions regarding long-term safety 
remain unanswered. At least a dozen additional trials that 
examine STIs are currently recruiting patients and will help 
answer these questions. 
Papasavvas E, Kostman JR, Mounzer K, Grant RM, Gross R, et 
al. (2004) Randomized, controlled trial of therapy interruption in 
chronic HIV-1 infection. DOI: 10.1371/journal.pmed.0010064
The Icelandic population is now a part 
of a unique epidemiological study, which 
has involved investigating the genetic 
heritage of many of them. The reason that 
this experiment can be done is because 
of the remarkable records that exist in 
Iceland. Not only is there almost complete 
genealogical information dating back to 
the 18th century on all current (288,000) 
and many previous Icelanders (more 
than 600,000 in total), but in addition the 
country has an almost complete cancer 
registry dating from 1955. A company, 
deCODE Genetics, was set up to mine 
health-care data in Iceland, and to use 
it to assess the effect of genetics on 
health. Initially, the company attracted 
criticism, with some questioning the 
ethics of providing access to health-
care data for many disease projects to 
a for-proﬁ  t company. But the company 
has been supported by many Icelanders 
themselves, demonstrated by Icelanders 
donating blood samples with informed 
consent for research on multiple diseases, 
and now the project’s scientiﬁ  c value is 
becoming apparent.
One such analysis is the subject of 
a paper by Laufey Amundadottir and 
colleagues in this month’s PLoS Medicine 
that assesses how much genetic factors 
contribute to cancer risk across the whole 
Icelandic population. 
The paper looked at 27 different types 
of cancers (all those with more than 
200 cases) that had been registered 
between 1955 and 2002 and analysed the 
frequency of close and distant relatives 
also having that cancer, or another 
kind of cancer. Of the 27 cancers, 16 
showed signiﬁ  cant “familiality,” and for 
some this risk even extended to distant 
(that is, third- to ﬁ  fth-degree) relatives. 
The seven cancers with the highest 
increased familial occurrence both in 
close and distant relatives were breast, 
prostate, stomach, lung, colon, kidney, 
and bladder cancers. And, interestingly, 
three cancers—stomach, lung, and colon 
DOI: 10.1371/journal.pmed.0010069.g001
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cancer—were also seen more frequently 
in mates of patients, indicating a shared 
environmental risk factor. And for some 
cancers there was a familial association 
with other cancers, for example, relatives 
of individuals with stomach, colon, rectal, 
or endometrial cancer were more likely to 
have any of these cancers. 
Cathryn Lewis, the academic editor 
for the paper comments on the 
study’s strengths.  “This level of family 
relationship and clinical diagnosis 
is rarely available from interviewing 
patients and family members. The size 
of the study (over 600,000 individuals, 
with 32,000 cancer cases) and the high 
quality of data enables the authors 
to detect subtle effects across distant 
relationships.”  
How robust are these data, and 
what do they mean for the biological 
understanding of cancer? As Lewis 
says,  “Although the current study is 
impressive in its size and scope, even 
here, the sample size becomes an issue, 
with the most convincing results seen 
in the most common cancers.” Certainly 
not all the ﬁ  ndings are surprising; some 
rare cancers are already known to be 
associated with particular genetic defects, 
and syndromes that predispose to 
multiple cancers have been described, for 
example, that of Hereditary Nonpolyposis 
Colorectal Cancer. Other associations are 
more intriguing—the cluster of related 
cancers that include prostate, kidney, 
and bladder could possibly have a 
developmental origin, since all arise from 
the same part of the embryo.
So, by highlighting these subtle 
links, the study’s particular value may 
become apparent: deciding future 
avenues of investigation in the complex 
interrelationships that interact to 
produce cancer.
Amundadottir LT, Thorvaldsson S, 
Gudbjartsson DF, Sulem P, Kristjansson 
K, et al. (2004) Cancer as a complex 
phenotype: Pattern of cancer distribution 
within and beyond the nuclear family. DOI: 
10.1371/journal.pmed.0010065
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